These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25499124)

  • 1. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
    McKimm-Breschkin JL; Barrett S
    Antiviral Res; 2015 Feb; 114():62-6. PubMed ID: 25499124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
    Fujisaki S; Imai M; Takashita E; Taniwaki T; Xu H; Kishida N; Yokoyama M; Sato H; Tashiro M; Odagiri T
    J Infect Chemother; 2013 Oct; 19(5):891-5. PubMed ID: 23529501
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
    Kode SS; Pawar SD; Tare DS; Keng SS; Hurt AC; Mullick J
    Vet Microbiol; 2019 Aug; 235():21-24. PubMed ID: 31282375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
    Kubo S; Tokumitsu A; Tomozawa T; Kakuta M; Yamashita M
    J Infect Chemother; 2012 Feb; 18(1):69-74. PubMed ID: 21881920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
    Hurt AC; Lowther S; Middleton D; Barr IG
    Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
    Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
    Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
    Meeprasert A; Khuntawee W; Kamlungsua K; Nunthaboot N; Rungrotmongkol T; Hannongbua S
    J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
    Vavricka CJ; Li Q; Wu Y; Qi J; Wang M; Liu Y; Gao F; Liu J; Feng E; He J; Wang J; Liu H; Jiang H; Gao GF
    PLoS Pathog; 2011 Oct; 7(10):e1002249. PubMed ID: 22028647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
    Yamashita M
    Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.
    Andreev K; Jones JC; Seiler P; Kandeil A; Webby RJ; Govorkova EA
    Antiviral Res; 2024 Sep; 229():105959. PubMed ID: 38986873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
    Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
    J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
    Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
    Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
    Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
    Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
    Tomozawa T; Hoshino K; Yamashita M; Kubo S
    J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.